Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York City, NY gives an overview of the updated analysis of overall survival (OS) of the randomized Phase III trial of idelalisib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia (CLL) (NCT01569295). In terms of safety, the addition of idelalisib to the bendamustine/rituximab backbone increases the risk of infection and risk of sepsis. There is also toxicity to be expected from idelalisib, including diarrhea, transaminitis and risk of cytomegalovirus (CMV) and pneumocystis jirovecii pneumonia (PJP) infection. The updated analysis shows that there is a sustained OS advantage of adding idelalisib. Prof. Zelenetz points out that the trial cannot answer the question if we need bendamustine as it was not designed to do so. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.